PET-CT to Assess Brain Damage in Cardiac Arrest Patients
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorCapital Medical University
About this trial
This was a single-center, observational study. Patients with successful cardiopulmonary resuscitation (CPR) will be transferred to the emergency intensive care unit for further standardized management. After successful return of spontaneous circulation (ROSC) for 72 hours and hemodynamic stability for 24 hours, the patients underwent positron emission computed tomography (PET-CT) examination after resuscitation. The supervising physician accompanied the patient and used monitors to monitor vital signs during the examination. Patients who were on ventilators were mechanically ventilated with a magnetic ventilator (HAMILTON-MRI, United States). In addition to conventional cerebral oxygen metabolism, cerebral blood flow, oxygen extraction fraction, cerebral blood volume and other indicators were added in this experiment. These indicators can evaluate the patient's cerebral metabolism, cerebral blood flow and cerebral blood oxygen damage degree. The neurological outcome was followed up 6 months after onset according to the cerebral performance category（CPC）.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
age ≥18 years.
sustained hemodynamic stability for ≥24h.
the patients were unconscious and not able to obey verbal commands. • Advanced life support and target temperature management within 6 hours of return of spontaneous circulation (ROSC).
Disqualifiers
Patients with hemodynamic instability.
Patients who could not complete cranial PET-CT examination for special reasons. • Patients during pregnancy.
Patients who combined traumatic brain injury, stroke, cerebral hemorrhage and other diseases.
Patients whose family members did not agree to be enrolled.
Trial population
Patients after successful cardiopulmonary resuscitation (CPR) were transferred to the emergency intensive care unit for further standardized management.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
No interventions
Other interventionNo interventions
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Neurologic prognosis
Patients will be followed up for neurologic prognosis according to the Cerebral Performance Category Scale（CPC）at 6 months after disease onset.The CPC score was divided into five grades. Grade 1 represented intact brain function, the patient was awake and alert, and had the ability to live and work normally. Grade 2 represents moderate cerebral disability, in which the person is awake and able to work part of the time in a specific environment or perform daily activities independently; Grade 3, severe cerebral disability: the person is awake but dependent on others for daily assistance and retains limited cognition; Grade 4 represents coma and vegetative state, the patient is unconscious, unconscious to the environment, and has no cognitive ability; Level 5 represents death, with the patient confirmed as brain death or death by traditional criteria. According to the CPC score, grade 1-2 was defined as good neurological outcome, and grade 3-5 was defined as poor neurological outcome.
Time frame
6 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: